Telomir Pharmaceuticals (NASDAQ:TELO) Stock Rating Upgraded by Maxim Group

Telomir Pharmaceuticals (NASDAQ:TELO) was upgraded by equities research analysts at Maxim Group to a “strong-buy” rating in a research note issued on Thursday, Zacks reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $4.00.

Telomir Pharmaceuticals Trading Up 9.8%

Shares of NASDAQ TELO opened at $1.23 on Thursday. The company has a market capitalization of $84.60 million, a price-to-earnings ratio of -1.35 and a beta of -0.25. The business has a 50 day simple moving average of $1.15 and a 200-day simple moving average of $1.25. Telomir Pharmaceuticals has a twelve month low of $0.89 and a twelve month high of $2.09.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.72).

Hedge Funds Weigh In On Telomir Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC acquired a new position in shares of Telomir Pharmaceuticals during the 2nd quarter valued at $29,000. World Investment Advisors acquired a new stake in shares of Telomir Pharmaceuticals in the fourth quarter valued at $47,000. Bank of New York Mellon Corp bought a new position in Telomir Pharmaceuticals during the second quarter valued at about $66,000. Finally, BlackRock Inc. bought a new position in Telomir Pharmaceuticals during the second quarter valued at about $359,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases and conditions associated with aging. The company’s research is centered on telomere biology, an area involving the protective structures at the ends of chromosomes that generally shorten as cells divide and age.

Telomir’s lead product candidate is TELOMIR-1, an orally administered small-molecule compound being investigated for its potential to address telomere shortening and support healthier cellular aging.